Suppression of hepatitis C virus replication by cyclin-dependent kinase inhibitors

Antiviral Research

Volumn 108, Issue 1, 2014, Pages 79-87

  Munakata, Tsubasa ^a,b   Inada, Makoto ^b   Tokunaga, Yuko ^a   Wakita, Takaji ^c   Kohara, Michinori ^a   Nomoto, Akio ^b,d  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d INSTITUTE OF MICROBIAL CHEMISTRY   (Japan)

Author keywords

CDK inhibitor; Chimera mice; HCV; Rb; Replicon

Indexed keywords

AMINOPURVALANOL A; ANTIVIRUS AGENT; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; FASCAPLYSIN; HOST FACTOR; INDIRUBIN 3' MONOXIME 5 SULFONIC ACID; PEGINTERFERON ALPHA2A; RETINOBLASTOMA PROTEIN; ROSCOVITINE; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE; ENZYME INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; ENZYME PHOSPHORYLATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; VIRUS INHIBITION; VIRUS REPLICATION; ANTAGONISTS AND INHIBITORS; CELL LINE; DRUG DEVELOPMENT; DRUG EFFECTS; HEPACIVIRUS; IC50; PHYSIOLOGY; PROCEDURES;

ANTIVIRAL AGENTS; CELL LINE; CYCLIN-DEPENDENT KINASES; DRUG DISCOVERY; ENZYME INHIBITORS; HEPACIVIRUS; HUMANS; INHIBITORY CONCENTRATION 50; VIRUS REPLICATION;

EID: 84902592459     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.05.011     Document Type: Article

References (52)

1. R.J. Barnard, C.M. McHale, W. Newhard, C.A. Cheney, D.J. Graham, A.L. Himmelberger, J. Strizki, P.M. Hwang, A.A. Rivera, J.D. Reeves, D. Nickle, M.J. Dinubile, D.J. Hazuda, and N. Mobashery Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis Virology 443 2013 278 284
2. K. Buchkovich, L.A. Duffy, and E. Harlow The retinoblastoma protein is phosphorylated during specific phases of the cell cycle Cell 58 1989 1097 1105 (Pubitemid 19238187)
3. M.L. Chang, T.H. Chen, M.Y. Chang, and C.T. Yeh Cell cycle perturbation in the hepatocytes of HCV core transgenic mice following common bile duct ligation is associated with enhanced p21 expression J. Med. Virol. 81 2009 467 472
4. S.P. Chellappan, S. Hiebert, M. Mudryj, J.M. Horowitz, and J.R. Nevins The E2F transcription factor is a cellular target for the RB protein Cell 65 1991 1053
5. H.Z. Chen, S.Y. Tsai, and G. Leone Emerging roles of E2Fs in cancer: an exit from cell cycle control Nat. Rev. Cancer 9 2009 785 797
6. Y.H. Chow, X.D. Zhu, L. Liu, B.R. Schwartz, X.Z. Huang, J.M. Harlan, and L.M. Schnapp Role of Cdk4 in lymphocyte function and allergen response Cell Cycle 9 2010 4922 4930
7. R. De Francesco, and G. Migliaccio Challenges and successes in developing new therapies for hepatitis C Nature 436 2005 953 960 (Pubitemid 41191671)
8. S. Elowe Bub1 and BubR1: at the interface between chromosome attachment and the spindle checkpoint Mol. Cell. Biol. 31 2011 3085 3093
9. J.J. Feld, and J.H. Hoofnagle Mechanism of action of interferon and ribavirin in treatment of hepatitis C Nature 436 2005 967 972 (Pubitemid 41191673)
10. M. Honda, S. Kaneko, E. Matsushita, K. Kobayashi, G.A. Abell, and S.M. Lemon Cell cycle regulation of hepatitis C virus internal ribosomal entry site-directed translation Gastroenterology 118 2000 152 162 (Pubitemid 30020383)
11. M. Ikeda, M. Yi, K. Li, and S.M. Lemon Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells J. Virol. 76 2002 2997 3006 (Pubitemid 34184884)
12. J.-y. Kato, M. Matsuoka, K. Polyak, J. Massague, and C.J. Sherr Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation Cell 79 1994 487
13. T. Kato, T. Date, M. Miyamoto, A. Furusaka, K. Tokushige, M. Mizokami, and T. Wakita Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon Gastroenterology 125 2003 1808 1817 (Pubitemid 37500445)
14. E.B. Keeffe Future treatment of chronic hepatitis C Antivir. Ther. 12 2007 1015 1025 (Pubitemid 350114981)
15. L. Khidr, and P.L. Chen RB, the conductor that orchestrates life, death and differentiation Oncogene 25 2006 5210 5219 (Pubitemid 44299079)
16. E.S. Knudsen, and J.Y. Wang Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites J. Biol. Chem. 271 1996 8313 8320 (Pubitemid 26108665)
17. A.G. Knudson Jr. Mutation and cancer: statistical study of retinoblastoma Proc. Natl. Acad. Sci. U.S.A. 68 1971 820 823
18. V. Krystof, and S. Uldrijan Cyclin-dependent kinase inhibitors as anticancer drugs Curr. Drug Targets 11 2010 291 302
19. Y.H. Kwon, A. Jovanovic, M.S. Serfas, H. Kiyokawa, and A.L. Tyner P21 functions to maintain quiescence of p27-deficient hepatocytes J. Biol. Chem. 277 2002 41417 41422 (Pubitemid 35257442)
20. D. Lamarre, P.C. Anderson, M. Bailey, P. Beaulieu, G. Bolger, P. Bonneau, M. Bos, D.R. Cameron, M. Cartier, M.G. Cordingley, A.M. Faucher, N. Goudreau, S.H. Kawai, G. Kukolj, L. Lagace, S.R. LaPlante, H. Narjes, M.A. Poupart, J. Rancourt, R.E. Sentjens, R. St George, B. Simoneau, G. Steinmann, D. Thibeault, Y.S. Tsantrizos, S.M. Weldon, C.L. Yong, and M. Llinas-Brunet An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus Nature 426 2003 186 189 (Pubitemid 37442587)
21. C. Lin, C.A. Gates, B.G. Rao, D.L. Brennan, J.R. Fulghum, Y.P. Luong, J.D. Frantz, K. Lin, S. Ma, Y.Y. Wei, R.B. Perni, and A.D. Kwong In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061 J. Biol. Chem. 280 2005 36784 36791 (Pubitemid 41587758)
22. J. Lupberger, M.B. Zeisel, F. Xiao, C. Thumann, I. Fofana, L. Zona, C. Davis, C.J. Mee, M. Turek, S. Gorke, C. Royer, B. Fischer, M.N. Zahid, D. Lavillette, J. Fresquet, F.L. Cosset, S.M. Rothenberg, T. Pietschmann, A.H. Patel, P. Pessaux, M. Doffoel, W. Raffelsberger, O. Poch, J.A. McKeating, L. Brino, and T.F. Baumert EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy Nat. Med. 17 2011 589 595
23. M.J. Macartney, D. Irish, S.H. Bridge, A. Garcia-Diaz, C.L. Booth, A.L. McCormick, W. Labbett, C. Smith, C. Velazquez, S. Tanwar, P. Trembling, M. Jacobs, G. Dusheiko, W. Rosenberg, and T. Haque Telaprevir or boceprevir based therapy for chronic hepatitis C infection: development of resistance-associated variants in treatment failure Antiviral Res. 105c 2014 112 117
24. M. Malumbres, and M. Barbacid Cell cycle, CDKs and cancer: a changing paradigm Nat. Rev. Cancer 9 2009 153 166
25. M.P. Manns, E. Gane, M. Rodriguez-Torres, A. Stoehr, C.T. Yeh, P. Marcellin, R.T. Wiedmann, P.M. Hwang, L. Caro, R.J. Barnard, and A.W. Lee Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C: a randomized phase II study Hepatology 56 2012 884 893
26. H. Matsushime, M.E. Ewen, D.K. Strom, J.Y. Kato, S.K. Hanks, M.F. Roussel, and C.J. Sherr Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins Cell 71 1992 323 334
27. C.N. Mayhew, S.L. Carter, S.R. Fox, C.R. Sexton, C.A. Reed, S.V. Srinivasan, X. Liu, K. Wikenheiser-Brokamp, G.P. Boivin, J.S. Lee, B.J. Aronow, S.S. Thorgeirsson, and E.S. Knudsen RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis Gastroenterology 133 2007 976 984 (Pubitemid 47374137)
28. S.J. McClue, D. Blake, R. Clarke, A. Cowan, L. Cummings, P.M. Fischer, M. MacKenzie, J. Melville, K. Stewart, S. Wang, N. Zhelev, D. Zheleva, and D.P. Lane In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine) Int. J. Cancer 102 2002 463 468 (Pubitemid 35315999)
29. S.J. McClue, and I. Stuart Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo Drug Metab. Dispos. 36 2008 561 570 (Pubitemid 351397982)
30. L. Meijer, A. Borgne, O. Mulner, J.P. Chong, J.J. Blow, N. Inagaki, M. Inagaki, J.G. Delcros, and J.P. Moulinoux Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5 Eur. J. Biochem. 243 1997 527 536 (Pubitemid 27060443)
31. T. Munakata, Y. Liang, S. Kim, D.R. McGivern, J. Huibregtse, A. Nomoto, and S.M. Lemon Hepatitis C virus induces E6AP-dependent degradation of the retinoblastoma protein PLoS Pathog. 3 2007 1335 1347 (Pubitemid 47510285)
32. T. Munakata, M. Nakamura, Y. Liang, K. Li, and S.M. Lemon Down-regulation of the retinoblastoma tumor suppressor by the hepatitis C virus NS5B RNA-dependent RNA polymerase Proc. Natl. Acad. Sci. U.S.A. 102 2005 18159 18164 (Pubitemid 41798518)
33. E.A. Musgrove, C.E. Caldon, J. Barraclough, A. Stone, and R.L. Sutherland Cyclin D as a therapeutic target in cancer Nat. Rev. Cancer 11 2011 558 572
34. S. Nakagawa, T. Umehara, C. Matsuda, S. Kuge, M. Sudoh, and M. Kohara Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice Biochem. Biophys. Res. Commun. 353 2007 882 888 (Pubitemid 46080379)
35. B.P. Nutley, F.I. Raynaud, S.C. Wilson, P.M. Fischer, A. Hayes, P.M. Goddard, S.J. McClue, M. Jarman, D.P. Lane, and P. Workman Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse Mol. Cancer Ther. 4 2005 125 139 (Pubitemid 40276782)
36. J.-M. Pawlotsky Hepatitis: HCV variability, the immune system and resistance to antiviral drugs Nat. Rev. Gastroenterol. Hepatol. 6 2009 383
37. F. Poordad, E. Lawitz, K.R. Reddy, N.H. Afdhal, C. Hezode, S. Zeuzem, S.S. Lee, J.L. Calleja, R.S. Brown Jr., A. Craxi, H. Wedemeyer, L. Nyberg, D.R. Nelson, L. Rossaro, L. Balart, T.R. Morgan, B.R. Bacon, S.L. Flamm, K.V. Kowdley, W. Deng, K.J. Koury, L.D. Pedicone, F.J. Dutko, M.H. Burroughs, K. Alves, J. Wahl, C.A. Brass, J.K. Albrecht, and M.S. Sulkowski Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection - a randomized trial Gastroenterology 145 2013 1035-1044.e1035
38. S.G. Rane, P. Dubus, R.V. Mettus, E.J. Galbreath, G. Boden, E.P. Reddy, and M. Barbacid Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia Nat. Genet. 22 1999 44 52
39. C.A. Reed, C.N. Mayhew, A.K. McClendon, and E.S. Knudsen Unique impact of RB loss on hepatic proliferation: tumorigenic stresses uncover distinct pathways of cell cycle control J. Biol. Chem. 285 2010 1089 1096
40. C. Sarrazin, T.L. Kieffer, D. Bartels, B. Hanzelka, U. Muh, M. Welker, D. Wincheringer, Y. Zhou, H.M. Chu, C. Lin, C. Weegink, H. Reesink, S. Zeuzem, and A.D. Kwong Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir Gastroenterology 132 2007 1767 1777 (Pubitemid 46677938)
41. F. Scholle, K. Li, F. Bodola, M. Ikeda, B.A. Luxon, and S.M. Lemon Virus-host cell interactions during hepatitis C virus RNA replication: impact of polyprotein expression on the cellular transcriptome and cell cycle association with viral RNA synthesis J. Virol. 78 2004 1513 1524 (Pubitemid 38095861)
42. V. Simanis, and P. Nurse The cell cycle control gene cdc2+ of fission yeast encodes a protein kinase potentially regulated by phosphorylation Cell 45 1986 261 268 (Pubitemid 16043429)
43. P. Simmonds, J. Bukh, C. Combet, G. Deleage, N. Enomoto, S. Feinstone, P. Halfon, G. Inchauspe, C. Kuiken, G. Maertens, M. Mizokami, D.G. Murphy, H. Okamoto, J.M. Pawlotsky, F. Penin, E. Sablon, I.T. Shin, L.J. Stuyver, H.J. Thiel, S. Viazov, A.J. Weiner, and A. Widell Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes Hepatology 42 2005 962 973 (Pubitemid 41401136)
44. T. Takeuchi, A. Katsume, T. Tanaka, A. Abe, K. Inoue, K. Tsukiyama-Kohara, R. Kawaguchi, S. Tanaka, and M. Kohara Real-time detection system for quantification of hepatitis C virus genome Gastroenterology 116 1999 636 642 (Pubitemid 29106771)
45. C. Tateno, Y. Yoshizane, N. Saito, M. Kataoka, R. Utoh, C. Yamasaki, A. Tachibana, Y. Soeno, K. Asahina, H. Hino, T. Asahara, T. Yokoi, T. Furukawa, and K. Yoshizato Near completely humanized liver in mice shows human-type metabolic responses to drugs Am. J. Pathol. 165 2004 901 912 (Pubitemid 39129297)
46. N. Teramoto, K. Pokrovskaja, L. Szekely, A. Polack, T. Yoshino, T. Akagi, and G. Klein Expression of cyclin D2 and D3 in lymphoid lesions Int. J. Cancer 81 1999 543 550 (Pubitemid 29203050)
47. H. Toyoshima, and T. Hunter P27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21 Cell 78 1994 67 74 (Pubitemid 24228301)
48. F. Uhlmann, C. Bouchoux, and S. Lopez-Aviles A quantitative model for cyclin-dependent kinase control of the cell cycle: revisited Philos. Trans. R. Soc. Lond. B Biol. Sci. 366 2011 3572 3583
49. T. Wakita, T. Pietschmann, T. Kato, T. Date, M. Miyamoto, Z. Zhao, K. Murthy, A. Habermann, H.G. Krausslich, M. Mizokami, R. Bartenschlager, and T.J. Liang Production of infectious hepatitis C virus in tissue culture from a cloned viral genome Nat. Med. 11 2005 791 796 (Pubitemid 41021213)
50. L. Waters, and M. Nelson New therapeutic options for hepatitis C Curr. Opin. Infect. Dis. 19 2006 615 622 (Pubitemid 44665469)
51. S.R. Whittaker, M.I. Walton, M.D. Garrett, and P. Workman The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway Cancer Res. 64 2004 262 272 (Pubitemid 38114107)
52. Z.Q. Yao, A. Eisen-Vandervelde, S. Ray, and Y.S. Hahn HCV core/gC1qR interaction arrests T cell cycle progression through stabilization of the cell cycle inhibitor p27Kip1 Virology 314 2003 271 282 (Pubitemid 37153316)